Physician profile
Michael Ngo
NPI 1730529439
$2,204.49
in general payments reported to CMS, 2019-2025
16 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $194 · 2021: $489 · 2022: $123 · 2023: $121 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $642.37 | 2019-2021 | |
| Eisai INC. | $243.83 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $238.64 | 2021 | |
| Abbott Laboratories | $151.63 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.72 | 2019 | |
| Abbvie INC. | $124.66 | 2021 | |
| Novo Nordisk INC | $123.71 | 2019 | |
| Pfizer INC. | $120.80 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $114.71 | 2019 | |
| Amgen INC. | $84.39 | 2019 | |
| Vyne Pharmaceuticals INC. | $76.75 | 2020-2021 | |
| Lilly USA, LLC | $59.00 | 2019 | |
| Sanofi Pasteur INC. | $48.86 | 2019 | |
| Biodelivery Sciences International, INC. | $23.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.03 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.